Systemic delivery of calcium channel blockers for hypertension through transdermal delivery - a review by AL-japairai, Khater Ahmed Saeed & Mahmood, Syed
 
Systemic Delivery of Calcium Channel Blockers for Hypertension 
through Transdermal Delivery - A Review 
Khater Ahmed Saeed AL-Japairai1, a, Syed Mahmood1, b* 
1Department of Pharmaceutical Engineering, Faculty of Chemical and Process Engineering 
Technology, University Malaysia Pahang, Gambang 26300, Malaysia. 
aKhater.11@hotmail.com, b syedmahmood@ump.edu.my 
Keywords: Hypertension, Transdermal drug delivery, Skin, Calcium channel blockers, 
Bioavailability. 
Abstract. Hypertension is a significant public health challenge, responsible for a substantial 
proportion of deaths and disability globally. Calcium Channel Blockers (CCBs) are an essential 
class for the treatment of hypertension. However, most of CCBs must be taken more than once daily 
due to their low oral bioavailability and limited half-life leading to non-compliance in patients. The 
development of delivery methods for CCBs is an ongoing effort to overcome the issues related to 
their delivery via their traditional forms. The administration of the drug through the skin for 
systemic delivery has been recognised as one of the potential routes in hypertension treatment, 
especially when drugs suffer from low bioavailability, undesirable side effects and short biological 
half-life following oral administration. The main limitation of transdermal drug delivery is the 
resistance barrier of skin layers to penetrant molecules. Remarkable research efforts have been 
made worldwide to minimise the skin barrier and to create transdermal systems of several CCBs via 
employing skin-enhancing potential. The persistent progress in this field is promising for 
development the transdermal dosage forms advance technology in the long term and being 
commercialised sooner rather than later. This review explores the investigations on the viability and 
applicability of systemic delivery of numerous CCBs through the skin. 
Introduction 
The most prevalent heart disease in the world is high blood pressure, also known as hypertension. 
Hypertension is the condition whereby systemic arterial pressure is increased beyond normal levels 
over long periods [1]. According to worldwide studies on disease burden 5.2 million deaths were 
attributed to heart disease in economically developed countries. In developing countries, this figure 
is almost doubled at 9.1 million deaths [2]. Treatment of chronic high blood pressure occurs over a 
long period, often burdening the patient with repeated administration of drugs in conventional form. 
As a result, treatment compliance among patients is often low [3]. 
     Transdermal drug delivery offers several advantages over traditional routes of drug 
administration: (1) by-passing the first-pass effect (2) lowering dosage size and frequency (3) 
extended drug therapeutic range (4) prolonged drug half-life (5) smaller variability in patients and 
across patients [4]. In transdermal delivery research, researchers are faced with the hurdle of 
crossing the skin barrier while avoiding trauma or irritation at the delivery site. The stratum 
corneum specifically is the skin layer that presents the biggest hurdle against delivery of the drugs 
transdermally [5]. 
     Extensive studies have been done to overcome the barrier property of the stratum corneum for 
effective transdermal drug delivery. Transdermal patches currently in use in clinical settings were 
developed as first-generation methods, and the properties of the drug limited them. The properties 
of the drug that limits the permeation were low molecular weight, lipophilicity, and effective at low 
dose. Third-generation transdermal delivery advances focused on high permeability through the 
stratum corneum while preserving the deeper tissue layers from damage [6, 7]. Microneedles, 
thermal ablation, microdermabrasion, electroporation and cavitational ultrasound were developed to 
achieve these objectives. 
Materials Science Forum Submitted: 2020-07-30
ISSN: 1662-9752, Vol. 1025, pp 204-208 Revised: 2020-10-23
© 2021 Trans Tech Publications Ltd, Switzerland Accepted: 2020-10-23
Online: 2021-03-30
All rights reserved. No part of contents of this paper may be reproduced or transmitted in any form or by any means without the written permission of Trans
Tech Publications Ltd, www.scientific.net. (#553994802, UNIVERSITY OF MALAYA, Malaysia-10/03/21,12:38:16)
 
     Therapeutics against hypertension can be categorized via their mode of actions; some common 
agents include thiazide diuretics, β-blockers, the ACE inhibitors, calcium channel blockers (CCBs) 
and angiotensin II receptor antagonists [8]. 
     Calcium channel blockers (CCBs), can be divided into two classes: dihydropyridines (DHP) and 
non-dihydropyridines (non-DHP). DHP class CCBs are clinically classified based on the difference 
in the formula and the length of their action to 1st, 2nd, 3rd, and 4th generations while non-DHP 
classified to benzothiazepines (Diltiazem) and phenylalkylamines (Verapamil) [9, 10]. Most of 
these drugs have negative physicochemical traits that pose a challenge to their delivery, including 
low bioavailability in the body, short half-life, poor absorbance across the skin, and adverse 
reactions as well as the majority of these drugs are susceptible to first-pass metabolism [11]. 
Transdermal delivery systems have become a viable method for CCB drugs due to their ability to 
avoid the pitfalls associated with delivery via conventional means. Our manuscript describes recent 
advances in CCB transdermal delivery research. 
Dihydropyridines 
Nifedipine. Nifedipine is a first-generation of DHD calcium channel blocker that is prescribed 
extensively in patients with hypertension and angina [12, 13]. The molecular weight of nifedipine is 
346.33, with a log P of 2.49, biological half-life of 2 h and 50 - 70% bioavailability [14]. Oral 
administration of nifedipine encounters pre-systemic metabolism phase in the GI tract that limits its 
bioavailability and absorption [15]. Nifedipine is a suitable drug for the development of transdermal 
delivery routes due to its low molecular weight, the small daily dose (10-60 mg). Development of 
an effective transdermal system will increase patient compliance [16]. 
Proniosomes are non-ionic surfactant vesicles in a microscopic lamellar structure formed by the 
admixture of non-ionic surfactants, with or without cholesterol which are subsequently hydrated in 
aqueous media to form niosomes [17]. Yasam et al. (2016) developed nifedipine loaded niosomes 
for the transdermal treatment of hypertension. The biodistribution analysis of nifedipine showed 
that the developed niosomal formulation maintained sustained-release concentration in the 
cardiovascular tissue [16]. 
     Felodipine. Commonly prescribed second-generation of dihydropyridine CCB agent against 
hypertension and angina is Felodipine. It is commercialised as a tablet (2.5-10 mg) for oral 
administration, and it has a bioavailability of 15-20% after going through pre-systemic metabolism 
[18]. Felodipine log P is 4.36, and the molecular weight is 384.26 Da. Its terminal elimination half-
life ranges from 7 to 21 h [14]. 
Yusuf et al. (2014), used a rotary evaporation sonication method to formulate transfersomal 
formulations of felodipine for enhancement of its transdermal delivery. Also, they investigated the 
parameters for optimisation of variable membrane compositions containing soya and egg lecithin 
and edge activator. The bioavailability of felodipine from the transdermal formulation was found to 
be 358.42% compared to oral administration. Confocal laser scanning microscopy provided further 
evidence of the fast penetration of drug to across dermal layers [18]. 
     Nisoldipine. Nisoldipine is a second-generation of dihydropyridine CCB. It is used alone or in 
combination with other drugs to manage hypertension and angina pectoris [19]. Nisoldipine is 
classified under BCS, as a class II drug; hence, nisoldipine has poor solubility but high permeability 
[20]. 
     El Maghraby et al. (2015) in their study reported the preparation of proniosomes for nisoldipine 
transdermal delivery. The proniosomes were either plain, contained lecithin, or permeation 
enhancers. The authors found that proniosomes increased nisoldipine transdermal flux up to 12 fold 
compared to an aqueous drug solution at maximal saturation (from 0.46 to 12.18 µg/cm2/h). The 
addition of lecithin to the formulation further improved transdermal flux values to 28.51µg/cm2/h 
[21]. 
     Amlodipine. Amlodipine belongs to the third-generation of dihydropyridine categories of CCBs, 
and the antihypertensive action of amlodipine is attributed to its ability to relax the vascular smooth 
muscle [22]. 
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Recently, Kapoor and colleagues investigated the effect of nanostructured lipid carriers (NLCs) for 
transdermal transport of amlodipine. The optimised amlodipine NLCs displayed enhanced 
transdermal flux (58.33 μg/cm2/h), low particle size (123.8 nm), and higher entrapment efficiency 
(88.11%). Experiments using Wistar rats showed increased bioavailability of the drug. At the same 
time, rhodamine red (RR)-loaded NLCs facilitated increased dye penetration into the deeper layers 
of the skin, as shown by CLSM [23]. 
     Cilnidipine. Cilnidipine is a fourth-generation of DHD calcium channel blocker used in the 
management of hypertension; it emerged as a good candidate for combination therapy [24]. 
Cilnidipine is a BCS Class II drug; it is highly lipid-soluble with a log P of 4.7, poorly soluble in 
aqueous, and has a low dissolution rate [25]. 
Khatoon et al. (2019) attempted to formulate cilnidipine loaded transfersomes for transdermal 
application. As per the published report, the final formulation showed small vesicle size (206.24 ± 
5.94 nm) with a useful polydispersity index (0.302 ± 0.034), sufficient drug entrapment (96.45 ± 
1.92%) and a good transdermal flux (27.72 ± 3.55 μg/cm2/h) [26]. 
Phenylalkylamines and Benzothiazepines.  
Transdermal researches of verapamil and diltiazem illustrated in Table 1. 
Table 1. Transdermal researches of verapamil and diltiazem 
Name of drug Chemical profile  Transdermal outcome  Reference  
Phenylalkylamines 
(Verapamil HCl) 
Log P (5.23) 
MW (491.07 Da) 
Low bioavailability 
around 20-30% 
Elastic liposomes for the 
delivery showed that elastic 
vesicles led to an enhanced 
transdermal flux (50.2 ± 4.52 
µg/cm2/h) of verapamil HCl 
as compared to liposomes 











Log P (3.09) 
MW (414.53 Da) 
Low bioavailability 
(40%) 
Diltiazem matrix films via the 
solvent casting method 
increased the transdermal of 
diltiazem to the highest levels 








Transdermal drug delivery systems may present a solution for effective CCB delivery, due to their 
ability to by-pass the pre-systemic metabolism, prolong drug action, and reduce non-compliance in 
patients. This review presents briefly transdermal delivery systems developed for CCBs to 
overcome the problems associated with conventional delivery formats. However, much work still 
needs to be carried out on transdermal delivery systems for CCBs to achieve effective therapeutic 
dosages for clinical use. 
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